In the Claims

1-69. **(canceled)**

70. **(original)** A method for treating glomerulonephritis in a mammal, comprising identifying a mammal having glomerulonephritis and administering to the mammal a therapeutically effective amount of an IFN-β therapeutic.

71. **(original)** The method of claim 70, wherein glomerulonephritis is selected from the group consisting of focal glomeruloscerosis, collapsing glomerulopathies, minimal change disease, crescentic glomerulonephritis, nephritic syndrome, nephrotic syndrome, primary glomerulonephritis, secondary glomerulonephritis, proliferative glomerulonephritis, membraneous glomerulonephritis, membranoproliferative glomerulonephritis, immune-complex glomerulonephritis, anti-glomerular basement membrane (anti-GBM) glomerulonephritis, pauci-immune glomerulonephritis, diabetic glomerulopathy, chronic glomerulonephritis, and hereditary nephritis.

72. **(currently amended)** The method of claim 70 ~~or 71~~, wherein the IFN-β therapeutic comprises mature IFN-β.

73. **(canceled)**

74. **(currently amended)** The method of ~~any one of claims 70-73~~ claim 70, wherein the IFN-β is human IFN-β.

75. **(original)** The method of claim 74, wherein the IFN-β is at least about 95% identical to full length mature human IFN-β having SEQ ID NO: 4.

76. **(original)** The method of claim 75, wherein the IFN-β comprises SEQ ID NO: 4.

77. **(currently amended)** The method of claim 74 ~~any one of claims 70-76~~, wherein the IFN-β is glycosylated.

78. **(canceled)**

79. **(original)** The method of claim 74, wherein the IFN-β is IFN-β-1a.

80. **(original)** The method of claim 74, wherein the IFN-β is IFN-β-1b.

81-84. **(canceled)**

85. **(currently amended)** The method of claim 70 ~~any one of claims 70-84~~, wherein the IFN-β therapeutic comprises a pegylated IFN-β.

86-98. **(canceled)**

99. **(currently amended)** The method of claim 74 ~~any one of claims 70-98~~, wherein the mammal is a human.

100-104. **(canceled)**

105. **(original)** A method for treating chronic renal failure in a mammal, comprising identifying a mammal having chronic renal failure and administering to the mammal a therapeutically effective amount of an IFN-β therapeutic.

106. **(original)** The method of claim 105, wherein the IFN-β therapeutic comprises mature IFN-β.

107. **(canceled)**

108. **(currently amended)** The method of claim 105 ~~any one of claims 105-107~~, wherein the IFN-β is human IFN-β.

109. **(original)** The method of claim 108, wherein the IFN-β is at least about 95% identical to full length mature human IFN-β having SEQ ID NO: 4.

110. **(original)** The method of claim 109, wherein the IFN-β comprises SEQ ID NO: 4.

111. **(currently amended)** The method of claim 108 ~~any one of claims 105-110~~, wherein the IFN-β is glycosylated.

112. **(canceled)**

113. **(original)** The method of claim 108, wherein the IFN-β is IFN-β-1a.

114. **(original)** The method of claim 108, wherein the IFN-β is IFN-β-1b.

115-118. **(canceled)**

119. **(currently amended)** The method of claim 105 ~~any one of claims 105-118~~, wherein the IFN-β therapeutic comprises a pegylated IFN-β.

120-132. **(canceled)**

133. **(currently amended)** The method of claim 108 ~~any one of claims 105-132~~, wherein the mammal is a human.

134-138. **(canceled)**